Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
ConditionSeasonal Allergic Rhinitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Tongren Hospital
About this trial
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Voluntarily sign the informed consent form.
Disqualifiers
Have any condition that are not suitable for participating in this study.
Trial design
Design model
Parallel
Treatments tested in this trial
Interleukin-4 receptor responders
Biological/VaccineInterleukin-4 receptor was injected subcutaneously.
Placebo
Other interventionPlacebo was injected subcutaneously.
Treatment groups
120 Participants
are divided into 2 treatment groupsGroup A: Interleukin-4 receptor respondersExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Average change from baseline in daily retrospective total nasal symptom score (rTNSS) at week 2.
Average change from baseline in daily retrospective total nasal symptom score (rTNSS) during treatment period. The Total Nasal Symptom Score (TNSS) is the sum of the four symptom scores of runny nose, nasal congestion, nasal itching, and sneezing, with each symptom scoring from 0 to 3.
Time frame
up to Week 2Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov